Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00883636 · ClinicalTrials.gov registry record
Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis
A clinical trial, sponsored by Northwell Health.
- Terminated
- Registry status
- 4
- Enrollment target
NCT00883636 is a clinical trial that was terminated before completion, run by Northwell Health. The registered enrollment target is 4 participants.
The verdict
NCT00883636 was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- 4 participants
- Enrollment target
Study Summary
The objective of this study is as follows: * Perform genetic analysis to define the prevalence of each of the known gene mutations in an unselected cohort of patients with focal segmental glomerulosclerosis (FSGS) * Perform a comprehensive assessment of cardiovascular status to determine the incidence of any cardiac abnormalities in patients with FSGS * Determine if patients with mutations in specific proteins are more likely to have cardiovascular abnormalities * Initiate long-term follow up in all patients to determine whether cardiac prognosis is related to any specific genetic abnormality
Interventions
- OTHER Cardiovascular Assessment
- OTHER Renal Assessment
- OTHER Genetic Evaluation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00883636
The ClinicalTrials.gov registry entry for NCT00883636 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cardiovascular Assessment is the first listed.
NCT00883636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00883636 about?
NCT00883636 is a clinical study titled "Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis". The objective of this study is as follows: * Perform genetic analysis to define the prevalence of each of the known gene mutations in an unselected cohort of patients with focal segmental glomerulosclerosis (FSGS) * Perform a comprehensive assessment of cardiovascular status to determine the incide...
What is the current status of trial NCT00883636?
This trial is currently terminated. The enrollment target is 4 participants. The study started on 2008-10. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00883636?
The interventions under investigation include: Cardiovascular Assessment (OTHER), Renal Assessment (OTHER), Genetic Evaluation (OTHER).
Who is sponsoring clinical trial NCT00883636?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.